Immunohistochemical characterization of the expression of matrix metalloproteinase - 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in the invasive endometrioid endometrial carcinoma
DOI:
https://doi.org/10.14739/2310-1237.2015.3.55613Keywords:
Carcinoma Of Endometrium, MMP-9, TIMP-1Abstract
Endometrial carcinoma is the most common gynecological malignancy in developed countries.
Aim. With the aim to determine MMP-9 and TIMP-1 expression levels in the invasive endometrioid endometrial carcinoma (EEC) cells and areas of the immunopositive cells in the center of the tumor and in the area of tumor invasion into the myometrium pathohistological, immunohistochemical and morphometric study of histological specimens of operative material of 56 women with pT1-4 stage of tumor was performed.
Methods and results. It was found that MMP-9 and TIMP-1 expression occurs in 100% of invasive EEC. The ММР-9 expression level in the cytoplasm of tumor cells is high – 129.11±2.38 CUOD, which is 2,2 times more than its level in normal proliferative endometrium – 59.45±9.58 CUOD (p <0.05 ). The TIMP-1 expression level is 9.58±2.68 CUOD that is 2.69 times more than the expression level of TIMP-1 in normal proliferative endometrium (3.56±0.35 CUOD, p <0.05) . MMP-9 immunopositive cells make up 50.78±0.91% of area of invasive EEC tissue section and TIMP-1 immunopositive cells make up 3.76±0.15% of area of tumor tissue section. That is statistically significantly more than in normal proliferative endometrium, which has 23.31±1.31% of ММР-9 immunopositive cells and 2.82±0.14% of TIMP-1 immunopositive cells of endometrial glands. Differences between high levels of MMP-9 in the center of EEC and in the tumor myometrial invasion zone, as well as differences between the very low expression levels of TIMP-1 in these regions of the tumor were not statistically significant. With increasing of EEC histological grade the MMP-9 and TIMP-1 expression levels significantly increase (p <0.05). There is direct weak correlation between the MMP-9 and TIMP-1 expression levels in the cells of EEC (Pearson coefficient r =+0.31). Direct strong correlation between the expression level of MMP-9 in the tumor cells and the grade of tumor (Pearson coefficient r =+0.71) is revealed.
Conclusion. The results of the study showed the increasing invasive capacity of EAE with the tumor grade increasing.
References
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71–96. doi: 10.3322/CA.2007.0010.
Aglund, K., Rauvala, M., Puistola, U., Angstrom, T., Turpeenniemi-Hujanen, T., Zackrission, B., Stendahl, U. (2004) Gelatinases A and B (MMP-2 and MMP9) in endometrial cancer – MMP9 correlates to the grade and the stage. Gynecol Oncol, 94, 699–704. doi: http://dx.doi.org/10.1016/j.ygyno.2004.06.028.
Di Nezza, L., Misajon, A., Zhang, J., Jobling, T., Quinn, M. A., Ostor, A. G., et al. (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer, 94, 1466–1475.
Chirco, R., Liu, X. W., Jung, K. K., & Kim, H. R. C. (2006) Novel functions of TIMPs in cell signaling. Cancer and Metastasis Reviews, 25(1), 99–113. doi: 10.1007/s10555-006-7893-x.
Curry, T. E., Jr., & Osteen, K. G. (2003) The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocrine Reviews, 4, 428–465. doi: 10.1210/er.2002-0005.
Amalinei, C., Cianga, C., Balan, R., Cianga, P., Guisca, S., & Caruntu, I.-D. (2011) Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium. Annals of Anatomy, 193(1), 43–55. doi: 10.1016/j.aanat.2010.09.009.
Yu, F., Jiang, Q.P., Zhou, Y., Yang, Zh., Yu, X., Wang, H., et al. (2012) Abnormal expression of matrix metalloproteinase-9 (MMP9) correlates with clinical course in Chinese patients with endometrial cancer. Disease Marker, 32, 321–327. doi: 10.3233/DMA-2011-0886.
Dabbs, D. J. (2010) Diagnostic Immunohistochemistry. New York: Ch. Livingstone.
Tumanskyi, V. O., Yevsieiev, A. V., Kovalenko, I. S., Zubko, M. D. ; Zaporizkyi derzhavnyi medychnyi universytet (patentee) (2015) Patent Ukrainy na korysnu model №99314 Ukraina, MPK (2015) G01N 21/00, G06K 9/00. Sposib fototsyfrovoi morfometrii imunohistokhimichnykh preparative [Ukraine patent for utility model №99314 Ukraine, morphometry immunohistochemical method fototsyfrovoyi drugs МПК (2015) G01N 21/00, G06K 9/00]. Biuleten, 10. [in Ukrainian].
Rasband, W. S. & ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, Retrieved from USA – http://imagej.nih.gov/ij/, 1997–2012.
Jeziorska, M., Nagase, H., Salamonsen, L. A., & Woolley, D. E. (1999) Immunolocalization of the matrix metalloproteinases gelatinase B and stromelysin 1 in human endometrium throughout the menstrual cycle. J Reproduction and Fertility, 107, 43–51. doi: 10.1530/jrf.0.1070043.
Jong-Ryeol, Choi, Tae-Hwa, Lee, Young-Lim, Oh, Chun-Jun, Lee, & Won-Gyu, Kim. (2008) Expressions of MMP-2, MMP-9, TIMP-1, and TIMP-2 as prognostic factors in endometrial cancer. Korean J Gynecol Oncol, 19(1), 57–67.
Wlaźlak, Е., Surkont, G., Kobos, J., Tyliński, W., Stetkiewicz, T., & Suzin, J. (2006) Expression of metalloproteinases MMP-1 and MMP-9 and tissue inhibitor of metalloproteinases TIMP-1 in cases of endometrial carcinoma and endometrial hyperplasia. Menopause Review, 6, 363–366.
Määtä, M., Soini, Y., Liakka, A., & Autio-Harmainen, H. (2000) Localization of MT1-MMP, TIMP-1, TIMP-2 and TIMP-3 messenger RNA in normal, hyperplastic and neoplastic endometrium. Enhanced expression by endometrial carcinomas is associated with low differentiation. Am J Clinical Pathology, 114, 402–411. doi: http://dx.doi.org/10.1093/ajcp/114.3.402.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
